title: Newer developments in therapy for endemic mycoses.
abstract: In the 1960s and 1970s, amphotericin B was the only effective therapy for serious systemic endemic fungal infections due to Histoplasma capsulatum, Blastomyces dermatitidis, and Sporothrix schenckii. In the 1980s, ketoconazole was introduced as therapy for endemic mycoses; after this antifungal agent was introduced, some of these infections could be treated orally in an outpatient setting rather than intravenously in an inpatient setting. The 1990s have become the triazole era. It is now standard practice to treat nonmeningeal, non-life-threatening histoplasmosis and blastomycosis orally on an outpatient basis; the drug of choice for this treatment is itraconazole. Itraconazole also has proved useful as treatment for histoplasmosis in patients infected with human immunodeficiency virus. Although itraconazole has not yet been approved for the treatment of sporotrichosis, in preliminary studies it has been shown to be effective therapy not only for cutaneous and lymphocutaneous sporotrichosis but also for disseminated infection with S. schenckii.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
authors.forename: C A
authors.initials: CA
authors.lastname: Kauffman
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001759:Blastomycosis / Q000188:drug therapy; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy*; D013174:Sporotrichosis / Q000188:drug therapy
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole